SCHEMBL4336074

SCHEMBL4336074

NC(=S)N(CCO)N=Cc1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
MAPT P10636 6/20 0.47
MEN1 O00255 5/20 0.47
LMNA P02545 5/20 0.47
KMT2A Q03164 5/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALOX12 P18054 1/20 0.47
MAPK1 P28482 3/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.45
GAA P10253 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
RCE1 Q9Y256 1/20 0.43
NPFFR1 Q9GZQ6 3/20 0.42
NPFFR2 Q9Y5X5 3/20 0.42
POLB P06746 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336070 1.00 KDM4E (0.47) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4453469 0.87 KDM4E (0.49) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4341378 0.87 MAPT (0.48) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4344446 0.82 PTPN1 (0.51) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4457837 0.81 KDM4E (0.51) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4341232 0.81 KMT2A (0.58) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4341464 0.80 MAPT (0.49) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4341461 0.80 MAPT (0.49) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4323303 0.79 KDM4E (0.42) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL4329435 0.75 MAPT (0.58) KDM4EMAPTMEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KDM4E 3010/4885MAPT 3619/4885MEN1 4874/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 KDM4E 2338/4885MAPT 3876/4885MEN1 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.